Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
United States5 participantsStarted 2009-03
Plain-language summary
According to a recent estimate more than 280,000 people in the United States are affected by uveitis each year. This report, also estimated that uveitis is the reason for 30,000 new cases of blindness/year and up to 10 percent of all cases of blindness. The purpose of this trial is to determine the effectiveness of VEGF blockade with intravitreal pegaptanib in patients with uveitic CME.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male and female adults (\>18 years of age) with non infectious uveitis.
✓. Demonstrable (FA and/or OCT) bilateral or unilateral CME associated with uveitis of greater than 3 months but less than 1 years duration that is documented by two independent qualified observers.
✓. Best corrected VA between 20/40 and 20/200 as measured by the ETDRS chart attributable to CME in the study eye.
✓. Patients may be receiving systemic therapy for the treatment of their intraocular inflammation or cystoid macular edema, or may have been treated for the cystoid macular edema in the past.
✓. Anterior chamber inflammation equal to or greater than 1+ and vitreous inflammation equal to or greater than 1+ cell and 1+ haze as per the 'Standardization of Uveitis' working group definition.
✓. Females of child bearing potential must agree to utilize effective contraception during the study and two months after the last dose of study medication.
✓. Male study patients will agree to use effective contraception.
✓. Ability to give informed consent.
Exclusion criteria
✕. Allergy to pegaptanib or any of its components
✕. Diabetic retinopathy, macular degeneration or any other ocular condition affecting the study eye that may cause vision loss or in the opinion of the study investigator would interfere with the evaluation of the efficacy of Macugen for the treatment of uveitis associated CME.